USD 0.0
(-99.8%)
Breakdown | 2022 | 2021 | 2020 | 2019 | 2016 | 2015 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | 117.01 Million | 101.89 Million |
Net Income | - | - | - | - | -24.4 Million | -7.02 Million |
Depreciation & Amortization | - | - | - | - | 2.2 Million | 435 Thousand |
Deferred income taxes | - | - | - | - | -6.74 Million | -2.33 Million |
Stock-based compensation | - | - | - | - | 190 Thousand | 72 Thousand |
Change in working capital | - | - | - | - | 110.27 Million | 101.92 Million |
Other non-cash items | - | - | - | - | 35.48 Million | 8.82 Million |
Investing Cash Flow | - | - | - | - | -1.67 Million | -8.53 Million |
Investments in PPE | - | - | - | - | -1.67 Million | -8.95 Million |
Acquisitions | - | - | - | - | - | 424 Thousand |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | - | - | - | - | - | - |
Financing Cash Flow | - | - | - | - | -118.4 Million | -93.19 Million |
Debt repayment | - | - | - | - | -74.47 Million | -94.63 Million |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | -694.59 Thousand |
Other Financing Activities | - | - | - | - | -43.92 Million | 1.44 Million |
Accounts receivables | - | - | - | - | -3.68 Million | 21.58 Million |
Accounts payables | - | - | - | - | 7.3 Million | 12.1 Million |
Inventory | - | - | - | - | 106.32 Million | 67 Million |
Other working capital | - | - | - | - | 3.95 Million | 34.92 Million |
Cash at beginning of period | - | - | - | - | 9.82 Million | 9.66 Million |
Cash at end of period | - | - | - | - | 6.69 Million | 9.82 Million |
Capital Expenditure | - | - | - | - | -1.67 Million | -8.95 Million |
Effect of forex changes on cash | - | - | - | - | -65 Thousand | -10 Thousand |
Net cash flow / Change in cash | - | - | - | - | -3.13 Million | 162 Thousand |
Free Cash Flow | - | - | - | - | 115.33 Million | 92.94 Million |
Breakdown | 2022 FY | 2021 FY | 2020 FY | 2019 FY | 2016 FY | 2015 FY |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | - | - | - | - | -24.4 Million | -7.02 Million |
Depreciation & Amortization | - | - | - | - | 2.2 Million | 435 Thousand |
Deferred income taxes | - | - | - | - | -6.74 Million | -2.33 Million |
Stock-based compensation | - | - | - | - | 190 Thousand | 72 Thousand |
Change in working capital | - | - | - | - | 110.27 Million | 101.92 Million |
Other non-cash items | - | - | - | - | 35.48 Million | 8.82 Million |
Investing Cash Flow | - | - | - | - | -1.67 Million | -8.53 Million |
Investments in PPE | - | - | - | - | -1.67 Million | -8.95 Million |
Acquisitions | - | - | - | - | - | 424 Thousand |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | - | - | - | - | - | - |
Financing Cash Flow | - | - | - | - | -118.4 Million | -93.19 Million |
Debt repayment | - | - | - | - | -74.47 Million | -94.63 Million |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | -694.59 Thousand |
Other Financing Activities | - | - | - | - | -43.92 Million | 1.44 Million |
Accounts receivables | - | - | - | - | -3.68 Million | 21.58 Million |
Accounts payables | - | - | - | - | 7.3 Million | 12.1 Million |
Inventory | - | - | - | - | 106.32 Million | 67 Million |
Other working capital | - | - | - | - | 3.95 Million | 34.92 Million |
Cash at beginning of period | - | - | - | - | 9.82 Million | 9.66 Million |
Cash at end of period | - | - | - | - | 6.69 Million | 9.82 Million |
Capital Expenditure | - | - | - | - | -1.67 Million | -8.95 Million |
Effect of forex changes on cash | - | - | - | - | -65 Thousand | -10 Thousand |
Net cash flow / Change in cash | - | - | - | - | -3.13 Million | 162 Thousand |
Free Cash Flow | - | - | - | - | 115.33 Million | 92.94 Million |
GUJCONT
7685
4689
IONAF
GSK
DHANUKA